One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema
Top Cited Papers
- 1 August 2012
- journal article
- research article
- Published by Elsevier BV in Ophthalmology
- Vol. 119 (8), 1658-1665
- https://doi.org/10.1016/j.ophtha.2012.02.010
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) StudyOphthalmology, 2010
- Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)Diabetes Care, 2010
- ANGIOGENIC AND INFLAMMATORY MARKERS IN THE INTRAOCULAR FLUID OF EYES WITH DIABETIC MACULAR EDEMA AND INFLUENCE OF THERAPY WITH BEVACIZUMABRetina, 2010
- Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaOphthalmology, 2010
- Pathophysiology of Diabetic Macular EdemaInternational Ophthalmology Clinics, 2009
- A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular EdemaOphthalmology, 2007
- Comparison of the Modified Early Treatment Diabetic Retinopathy Study and Mild Macular Grid Laser Photocoagulation Strategies for Diabetic Macular EdemaAmerican Journal of Ophthalmology, 2007
- Anti‐VEGF Aptamer (Pegaptanib) Therapy for Ocular Vascular DiseasesAnnals of the New York Academy of Sciences, 2006
- The role of growth factors in the pathogenesis of diabetic retinopathyExpert Opinion on Investigational Drugs, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003